Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
DiagnosTear Technologies, Inc. ( (TSE:DTR) ) has shared an announcement.
DiagnosTear Technologies Inc. has announced a non-brokered private placement of 1,400,000 units at $0.50 per unit, aiming to raise $700,000. The proceeds will be used for working capital and general corporate purposes. Each unit includes one common share and one warrant, exercisable at $1.00 within 18 months. This move is expected to bolster the company’s financial position, supporting its ongoing development of diagnostic solutions in the ophthalmic industry. The offering is not registered under the U.S. Securities Act, limiting its sale to specific jurisdictions.
More about DiagnosTear Technologies, Inc.
DiagnosTear Technologies Inc. is a leading ophthalmic company focused on developing and commercializing innovative diagnostic solutions for managing eye diseases. Their flagship technology, TeaRx™, is a diagnostic platform for rapid, Point-of-Care Testing (POCT) of ophthalmic pathologies using non-invasively collected tear fluid. The company offers a CE-IVD and Israeli MoH-approved test for Dry Eye Syndrome and is expanding its pipeline to include tests for other ophthalmic conditions such as adenoviral conjunctivitis, Herpetic Keratitis, and Allergic conjunctivitis.
Average Trading Volume: 12,497
For a thorough assessment of DTR stock, go to TipRanks’ Stock Analysis page.